Rheumatoid Arthritis
The last day was jammed with important reports and research including the late breaking abstracts.
Curcumin, the active constituent of turmeric extract, has increasingly been promoted as a potential rheumatoid arthritis therapy, but data presented at ACR22 suggests that even in ideal situations, it is unable to do any better than placebo in replacing conventional RA therapies.
Richard Conway RichardPAConway
2 years 10 months ago
Curtis et al. Primary non-adherence to csDMARDs and b/tsDMARDs in RA/PsA/SpA. Medicare and commerically-insured patients. 20-44%! of new prescriptions not filled by 6 months. Higher for csDMARDs than b/tsDMARDs @RheumNow #ACR22 Abstr#2199 https://t.co/Pwg6GKu7Gg https://t.co/wPF0pu1UDa
David Liew drdavidliew
2 years 10 months ago
Which is better for CV risk in RA:
triple therapy DMARDs or TNFi?
TARGET study
n=159 using PET/CT surrogate (endpoint responsiveness👀)
- either led to benefit
- both equally good
- benefit *not* linked to change in DAS28
A direct CV effect of RA Rx?
ABST2215 #ACR22 @RheumNow https://t.co/4FPvSbfGsD
Richard Conway RichardPAConway
2 years 10 months ago
Singh @NamrataRheum et al. Frailty in patients treated bDMARD/tsDMARD assoc serious infections aHR 1.34, any infection aHR 1.18, hospitalisation aHR 1.34 (all relative non-frail). @RheumNow #ACR22 Abstr#2218 https://t.co/ONsTBq8ehB https://t.co/iTVANh5flk
Aurelie Najm AurelieRheumo
2 years 10 months ago
💤cognitive behavioural therapy 2 hours/wk for 6 wks for insomnia improves RA PROs at 26 wks
Insomnia Severity Index -9.8
RAID -1.4
PGA -13
Small sample size
wk6 trend improvement sleep efficiency 89% vs84% p=0.07 but not wk26
https://t.co/rpKdtbREYs Abs#2188 #ACR22 @RheumNow https://t.co/kEBcPAdIKW
Dr. Antoni Chan synovialjoints
2 years 10 months ago
Peresolimab humanized IgG1 mab
➢ stimulates PD-1 & physiological immune inhibitory pathways
➢ In RA phase 2 study, superior to placebo at Week 12 DAS28/CDAI
➢ safety events were similar between treatment groups
Emery P #L03 https://t.co/4Jd79CW5RA #ACR22 #ACRBest @RheumNow https://t.co/PSuLQgjYuz
Dr. John Cush RheumNow
2 years 10 months ago
Tonight at 7pm ET! Join our RA Topic Panel with panelists: Drs. Richard Conway, Aurelie Najm, David Liew, Janet Pope, Julian Segan
@RichardPAConway @AurelieRheumo @drdavidliew @Janetbirdope @JulianSegan #ACR22
https://t.co/hIH4WghLwN https://t.co/oKQbBnMiqQ
David Liew drdavidliew
2 years 10 months ago
Sometimes your RA pts are eligible for ICI cancer immunotherapy, but there’s hesitancy because of autoimmune risk/bad irAEs
@DanaFarber @MassGenBrigham:
more RA flares
but similar mortality, severe irAEs rates
Give them what they need!
ABST1667 @jeffsparks #ACR22 @RheumNow https://t.co/WdDP8IeIYG
Richard Conway RichardPAConway
2 years 10 months ago
Fletcher et al. Epidemiology RA-ILD 2004-18 in VA. Incidence increased from 340 to 970/100,000PY. Prevalence increased 1.7% to 4.5%. More common males (4.81% vs 2.53%) and over 60 @RheumNow #ACR22 Abstr#1638 https://t.co/AbPgLUPoDz https://t.co/V25xDUwLbu
Aurelie Najm AurelieRheumo
2 years 10 months ago
Peresolimab PD-1 agonist in RA Phase 2 RCT
Primary endpoint met w/ > improvement DAS28CRP Wk12
Also greater improvement of CDAI in both treated grps
TEAEs PBO 37% PER 300mg 40% PER 700mg 35%, 1 serious AE in PER 700mg
https://t.co/QtclWIWAw9
Abs#L03 #ACR22 @Rheumnow https://t.co/bLHP4JuNjt
Poster Hall